Dr. Lu received his bachelor’s degree in biochemistry from Fudan University in Shanghai, China, and his Ph.D. in molecular virology from the State University of New York at Buffalo. He was a post-doctoral fellow at the University of California, San Francisco, where he studied HIV transcriptional regulation and HIV-1 Nef protein and Nef associated proteins.
Dr. Lu worked at ONYX Pharmaceutical as a research scientist and continued work on HIV-Nef-associated kinases. At VIRxSYS Corporation, Dr. Lu served as a senior scientist and later a senior director for development of HIV- and SIV-based lentiviral vectors for clinical studies. He played an important role in the development of the first HIV-1 based lentiviral vector for human clinical studies for HIV-infected individuals. Later, he served as a senior scientific liaison at the United States Pharmacopeia, in charge of the Vaccines and Virology Expert Committee.
Currently, Dr. Lu is a product reviewer in the Office of Cellular, Tissues and Gene Therapies in the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration.
